Critical Comparison: Masimo (NASDAQ:MASI) versus 21st North (NASDAQ:ULGX)

21st North (OTCMKTS:ULGX) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for 21st North and Masimo, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
21st North 0 0 0 0 N/A
Masimo 0 1 4 0 2.80

Masimo has a consensus target price of $160.50, indicating a potential upside of 3.23%. Given Masimo’s higher probable upside, analysts clearly believe Masimo is more favorable than 21st North.

Volatility & Risk

21st North has a beta of 4.12, indicating that its share price is 312% more volatile than the S&P 500. Comparatively, Masimo has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

82.7% of Masimo shares are owned by institutional investors. 8.5% of 21st North shares are owned by insiders. Comparatively, 11.5% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares 21st North and Masimo’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
21st North N/A N/A N/A
Masimo 20.83% 17.32% 14.63%

Valuation & Earnings

This table compares 21st North and Masimo’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
21st North N/A N/A N/A N/A N/A
Masimo $858.29 million 9.66 $193.54 million $3.03 51.31

Masimo has higher revenue and earnings than 21st North.

Summary

Masimo beats 21st North on 8 of the 9 factors compared between the two stocks.

About 21st North

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software that monitors Masimo Root and Radical-7. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, long term care facilities, veterinarians and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.

Receive News & Ratings for 21st North Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 21st North and related companies with MarketBeat.com's FREE daily email newsletter.